The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

An experimental cancer vaccine has shown promising results in keeping pancreatic and colorectal cancers from coming back. In ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. In a recent update, Eli Lilly and Company announced the ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung ...

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...